These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

665 related items for PubMed ID: 11513935

  • 1. Antisense therapy in oncology: new hope for an old idea?
    Tamm I, Dörken B, Hartmann G.
    Lancet; 2001 Aug 11; 358(9280):489-97. PubMed ID: 11513935
    [Abstract] [Full Text] [Related]

  • 2. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
    Holmlund JT, Monia BP, Kwoh TJ, Dorr FA.
    Curr Opin Mol Ther; 1999 Jun 11; 1(3):372-85. PubMed ID: 11713802
    [Abstract] [Full Text] [Related]

  • 3. Antisense against protein kinase C-alpha mRNA makes sense for cancer therapy?
    Stewart A.
    Mol Med Today; 1997 Aug 11; 3(8):324. PubMed ID: 9269683
    [No Abstract] [Full Text] [Related]

  • 4. Antisense therapy directed to protein kinase C-alpha (Affinitak, LY900003/ISIS 3521): potential role in breast cancer.
    Roychowdhury D, Lahn M.
    Semin Oncol; 2003 Apr 11; 30(2 Suppl 3):30-3. PubMed ID: 12722024
    [Abstract] [Full Text] [Related]

  • 5. Antisense oligonucleotides in lung cancer.
    Pujol JL, Jacot W.
    Suppl Tumori; 2002 Apr 11; 1(4):S50-1. PubMed ID: 12415820
    [No Abstract] [Full Text] [Related]

  • 6. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT, Parkinson DR.
    Semin Oncol; 1997 Apr 11; 24(2):187-202. PubMed ID: 9129689
    [Abstract] [Full Text] [Related]

  • 7. Antisense oligonucleotides for cancer therapy-an overview.
    Stahel RA, Zangemeister-Wittke U.
    Lung Cancer; 2003 Aug 11; 41 Suppl 1():S81-8. PubMed ID: 12867066
    [Abstract] [Full Text] [Related]

  • 8. Antisense therapy in malignant diseases: status quo and quo vadis?
    Tamm I.
    Clin Sci (Lond); 2006 Apr 11; 110(4):427-42. PubMed ID: 16526947
    [Abstract] [Full Text] [Related]

  • 9. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
    Zhang C, Pei J, Kumar D, Sakabe I, Boudreau HE, Gokhale PC, Kasid UN.
    Methods Mol Biol; 2007 Apr 11; 361():163-85. PubMed ID: 17172711
    [Abstract] [Full Text] [Related]

  • 10. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
    Frankel SR.
    Semin Oncol; 2003 Apr 11; 30(2):300-4. PubMed ID: 12720157
    [Abstract] [Full Text] [Related]

  • 11. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
    Rudin CM, Holmlund J, Fleming GF, Mani S, Stadler WM, Schumm P, Monia BP, Johnston JF, Geary R, Yu RZ, Kwoh TJ, Dorr FA, Ratain MJ.
    Clin Cancer Res; 2001 May 11; 7(5):1214-20. PubMed ID: 11350886
    [Abstract] [Full Text] [Related]

  • 12. Antisense and/or immunostimulatory oligonucleotide therapeutics.
    Agrawal S, Kandimalla ER.
    Curr Cancer Drug Targets; 2001 Nov 11; 1(3):197-209. PubMed ID: 12188879
    [Abstract] [Full Text] [Related]

  • 13. Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human disease.
    Green DW, Roh H, Pippin J, Drebin JA.
    J Am Coll Surg; 2000 Jul 11; 191(1):93-105. PubMed ID: 10898188
    [No Abstract] [Full Text] [Related]

  • 14. Antisense oligonucleotides: the state of the art.
    Aboul-Fadl T.
    Curr Med Chem; 2005 Jul 11; 12(19):2193-214. PubMed ID: 16178780
    [Abstract] [Full Text] [Related]

  • 15. Cytotoxicity of etoposide in cancer cell lines in vitro after BCL-2 and C-RAF gene silencing with antisense oligonucleotides.
    Sypniewski D, Bednarek I, Gałka S, Loch T, Błaszczyk D, Sołtysik D.
    Acta Pol Pharm; 2013 Jul 11; 70(1):87-97. PubMed ID: 23610963
    [Abstract] [Full Text] [Related]

  • 16. Antisense approaches for the treatment of cancer.
    Monia BP, Holmlund J, Dorr FA.
    Cancer Invest; 2000 Jul 11; 18(7):635-50. PubMed ID: 11036471
    [No Abstract] [Full Text] [Related]

  • 17. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.
    Tolcher AW, Reyno L, Venner PM, Ernst SD, Moore M, Geary RS, Chi K, Hall S, Walsh W, Dorr A, Eisenhauer E.
    Clin Cancer Res; 2002 Aug 11; 8(8):2530-5. PubMed ID: 12171880
    [Abstract] [Full Text] [Related]

  • 18. Advancements of antisense oligonucleotides in treatment of breast cancer.
    Yang SP, Song ST, Song HF.
    Acta Pharmacol Sin; 2003 Apr 11; 24(4):289-95. PubMed ID: 12676065
    [Abstract] [Full Text] [Related]

  • 19. Antisense oligonucleotides: from design to therapeutic application.
    Chan JH, Lim S, Wong WS.
    Clin Exp Pharmacol Physiol; 2006 Apr 11; 33(5-6):533-40. PubMed ID: 16700890
    [Abstract] [Full Text] [Related]

  • 20. A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma.
    Advani R, Peethambaram P, Lum BL, Fisher GA, Hartmann L, Long HJ, Halsey J, Holmlund JT, Dorr A, Sikic BI.
    Cancer; 2004 Jan 15; 100(2):321-6. PubMed ID: 14716767
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.